DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $397,694,698 | -13.4% | 1,603,358 | -16.2% | 0.50% | -4.8% |
| Q2 2023 | $459,220,080 | +3.8% | 1,913,417 | +9.1% | 0.52% | 0.0% |
| Q1 2023 | $442,205,726 | +16.1% | 1,754,507 | +22.3% | 0.52% | +16.7% |
| Q4 2022 | $380,753,818 | +47.6% | 1,434,533 | +43.7% | 0.45% | +42.4% |
| Q3 2022 | $257,892,000 | -3.5% | 998,460 | -5.3% | 0.32% | +5.3% |
| Q2 2022 | $267,284,000 | -17.3% | 1,054,292 | -4.3% | 0.30% | +22.0% |
| Q1 2022 | $323,318,000 | -8.4% | 1,102,232 | +2.7% | 0.25% | -16.3% |
| Q4 2021 | $353,129,000 | +55.7% | 1,073,307 | +44.0% | 0.29% | +52.3% |
| Q3 2021 | $226,840,000 | +10.5% | 745,105 | -2.6% | 0.19% | +14.2% |
| Q2 2021 | $205,300,000 | +1023.0% | 765,018 | +841.8% | 0.17% | +550.0% |
| Q1 2021 | $18,282,000 | -6.0% | 81,227 | -7.2% | 0.03% | -7.1% |
| Q4 2020 | $19,452,000 | -4.3% | 87,565 | -7.2% | 0.03% | -17.6% |
| Q3 2020 | $20,330,000 | +23.9% | 94,409 | +1.7% | 0.03% | +21.4% |
| Q2 2020 | $16,410,000 | +17.0% | 92,802 | -8.4% | 0.03% | -3.4% |
| Q1 2020 | $14,023,000 | -23.7% | 101,311 | -15.4% | 0.03% | +11.5% |
| Q4 2019 | $18,382,000 | -26.2% | 119,763 | -30.6% | 0.03% | -38.1% |
| Q3 2019 | $24,921,000 | -66.2% | 172,548 | -66.6% | 0.04% | 0.0% |
| Q2 2019 | $73,776,000 | +195.8% | 516,225 | +173.3% | 0.04% | -2.3% |
| Q1 2019 | $24,940,000 | +29.5% | 188,913 | +1.2% | 0.04% | +16.2% |
| Q4 2018 | $19,257,000 | -5.0% | 186,756 | +0.1% | 0.04% | +12.1% |
| Q3 2018 | $20,270,000 | -7.2% | 186,538 | -15.7% | 0.03% | -13.2% |
| Q2 2018 | $21,832,000 | +5.5% | 221,233 | +4.7% | 0.04% | 0.0% |
| Q1 2018 | $20,690,000 | -1.9% | 211,322 | -6.8% | 0.04% | +2.7% |
| Q4 2017 | $21,098,000 | -20.8% | 226,732 | -27.0% | 0.04% | -22.9% |
| Q3 2017 | $26,645,000 | +2.7% | 310,618 | +1.0% | 0.05% | +2.1% |
| Q2 2017 | $25,941,000 | -17.8% | 307,392 | -16.7% | 0.05% | -17.5% |
| Q1 2017 | $31,564,000 | +6.1% | 369,032 | -3.5% | 0.06% | 0.0% |
| Q4 2016 | $29,753,000 | +13.3% | 382,225 | +14.1% | 0.06% | +14.0% |
| Q3 2016 | $26,249,000 | -61.2% | 334,853 | -50.3% | 0.05% | -24.2% |
| Q2 2016 | $67,640,000 | +117.1% | 674,074 | +105.2% | 0.07% | +4.8% |
| Q1 2016 | $31,160,000 | -15.8% | 328,481 | -17.5% | 0.06% | -17.1% |
| Q4 2015 | $36,991,000 | -4.5% | 398,228 | -12.4% | 0.08% | -8.4% |
| Q3 2015 | $38,724,000 | -2.1% | 454,458 | -1.6% | 0.08% | +6.4% |
| Q2 2015 | $39,549,000 | +14.4% | 462,081 | +13.5% | 0.08% | +14.7% |
| Q1 2015 | $34,559,000 | +11.6% | 407,062 | +12.6% | 0.07% | +6.2% |
| Q4 2014 | $30,973,000 | +11.6% | 361,362 | -1.1% | 0.06% | +6.7% |
| Q3 2014 | $27,751,000 | -9.0% | 365,235 | -5.7% | 0.06% | -11.8% |
| Q2 2014 | $30,491,000 | +14.3% | 387,294 | +8.9% | 0.07% | +47.8% |
| Q1 2014 | $26,678,000 | -5.6% | 355,695 | -2.8% | 0.05% | -9.8% |
| Q4 2013 | $28,252,000 | +30.2% | 365,955 | +16.9% | 0.05% | +21.4% |
| Q3 2013 | $21,694,000 | +25.3% | 312,955 | +14.4% | 0.04% | +10.5% |
| Q2 2013 | $17,316,000 | – | 273,545 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |